Report cover image

Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 13, 2024
Length 160 Pages
SKU # EMAR18558304

Description

Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032


Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032

Africa Contraceptive Drugs and Devices Market Outlook

The Africa contraceptive drugs and devices market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by trend towards the use of long-acting reversible contraceptives (LARCs) like IUDs and contraceptive implants across the region.

Contraceptive Drugs and Devices: Introduction

Contraceptive drugs and devices are methods used to prevent pregnancy. Contraceptive drugs, such as birth control pills, patches, and injections, typically use hormones to inhibit ovulation or alter cervical mucus. Devices, like condoms, diaphragms, intrauterine devices (IUDs), and contraceptive implants, create physical or chemical barriers to prevent sperm from reaching an egg. These methods vary in form, effectiveness, and duration of action, offering individuals options to choose based on their health, convenience, and family planning goals.

Key Trends in the Africa Contraceptive Drugs and Devices Market

There's a noticeable trend towards the use of Long-Acting Reversible Contraceptives (LARCs) like IUDs and contraceptive implants. These methods are gaining popularity due to their efficacy, ease of use, and long duration, reducing the need for frequent administration or user compliance.

The market is witnessing significant technological advancements and innovation in contraceptive products. This includes the development of contraceptives with fewer side effects, non-hormonal options, and user-friendly designs. There's also a focus on developing digital platforms and mobile applications for education, reminders, and tracking fertility, enhancing user engagement and compliance.

There's a global push to increase awareness of contraceptive options and sexual health education, particularly in emerging economies. Governments and non-profit organizations are working to improve accessibility and affordability of contraceptive drugs and devices, aiming to reduce the incidence of unintended pregnancies and support family planning initiatives.

The market is observing a shift towards personalized contraception, where individuals choose methods based on their lifestyle, health status, and future fertility intentions. Healthcare providers are focusing more on personalized consultations and offering a broader range of contraceptive options to meet individual needs.

Regulatory policies and ethical considerations continue to shape the contraceptive drugs and devices market. Changes in healthcare policies, funding for family planning services, and product approvals have significant impacts on market dynamics. There's also an ongoing dialogue about reproductive rights and access to contraception, influencing public perception and the adoption of contraceptive methods.

Africa Contraceptive Drugs and Devices Market Segmentation

Market Breakup by Product
  • Drugs
  • Oral Contraceptive Pills
  • Injectable Contraceptives
  • Topical Contraceptives
  • Devices
  • Condoms
  • Diaphragms
  • Cervical Caps
  • Sponges
  • Vaginal Ring
  • Intra Uterine Devices (IUD)
  • Others
  • Others
Market Breakup by Gender
  • Male
  • Female
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channel
  • Public Channel and NGOs
  • Others
Africa Contraceptive Drugs and Devices Market Overview

In Africa, the contraceptive drugs and devices market is evolving, influenced by increasing awareness of family planning and reproductive health. Efforts by governments and international organizations to promote sexual and reproductive health education are driving the demand for contraceptive solutions. The market shows a preference for long-acting reversible contraceptives (LARCs) like implants and IUDs, due to their efficacy and longer duration of action. However, challenges such as cultural attitudes, access to healthcare services, and affordability impact the adoption of contraceptive methods. Initiatives aimed at improving healthcare infrastructure, reducing the cost of contraceptives, and empowering women through education are key factors shaping the market's growth in the region.

Africa Contraceptive Drugs and Devices Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • AbbVie
  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd
  • Medicines360
  • Durex
  • Mankind Pharma
  • Johnson & Johnson
  • Gabler Medical
  • Sinapi Biomedical
  • Church & Dwight
  • CooperSurgical
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

160 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Africa Contraceptive Drugs and Devices Market Overview
3.1 Africa Contraceptive Drugs and Devices Market Historical Value (2017-2023)
3.2 Africa Contraceptive Drugs and Devices Market Forecast Value (2024-2032)
4 Africa Contraceptive Drugs and Devices Market Landscape
4.1 Africa Contraceptive Drugs and Devices Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.2 Africa Contraceptive Drugs and Devices Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Gender
5 Africa Contraceptive Drugs and Devices Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Africa Contraceptive Drugs and Devices Market Segmentation
6.1 Africa Contraceptive Drugs and Devices Market by Product
6.1.1 Market Overview
6.1.2 Drugs
6.1.2.1 Oral Contraceptive Pills
6.1.2.2 Injectable Contraceptives
6.1.2.3 Topical Contraceptives
6.1.3 Devices
6.1.3.1 Condoms
6.1.3.2 Diaphragms
6.1.3.3 Cervical Caps
6.1.3.4 Sponges
6.1.3.5 Vaginal Ring
6.1.3.6 Intra Uterine Devices (IUD)
6.1.3.7 Others
6.1.4 Others
6.2 Africa Contraceptive Drugs and Devices Market by Gender
6.2.1 Market Overview
6.2.2 Male
6.2.3 Female
6.3 Africa Contraceptive Drugs and Devices Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Clinics
6.3.5 Online Channel
6.3.6 Public Channel and NGOs
6.3.7 Others
7 Patent Analysis
7.1 Analysis by Type of Patent
7.2 Analysis by Publication year
7.3 Analysis by Issuing Authority
7.4 Analysis by Patent Age
7.5 Analysis by CPC Analysis
7.6 Analysis by Patent Valuation
7.7 Analysis by Key Players
8 Grants Analysis
8.1 Analysis by year
8.2 Analysis by Amount Awarded
8.3 Analysis by Issuing Authority
8.4 Analysis by Grant Application
8.5 Analysis by Funding Institute
8.6 Analysis by NIH Departments
8.7 Analysis by Recipient Organization
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding & Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Type of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Partnership and Collaborations Analysis
11.1 Analysis by Partnership Instances
11.2 Analysis by Type of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Regulatory Framework
13 Supplier Landscape
13.1 Merck & Co. Inc.
13.1.1 Financial Analysis
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Mylan N.V.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Pfizer Inc.
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Bayer AG
13.4.1 Financial Analysis
13.4.2 Financial Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 AbbVie
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Lupin Limited
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Medicines360
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Durex
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Mankind Pharma
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Johnson & Johnson
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Gabler Medical
13.12.1 Financial Analysis
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Sinapi Biomedical
13.13.1 Financial Analysis
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
13.14 Church & Dwight
13.14.1 Financial Analysis
13.14.2 Product Portfolio
13.14.3 Demographic Reach and Achievements
13.14.4 Mergers and Acquisitions
13.14.5 Certifications
13.15 CooperSurgical
13.15.1 Financial Analysis
13.15.2 Product Portfolio
13.15.3 Demographic Reach and Achievements
13.15.4 Mergers and Acquisitions
13.15.5 Certifications
14 Africa Contraceptive Drugs and Devices Market - Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us